Infection and Immunity, November 2000, p. 6176-6181, Vol. 68, No. 11
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Channing Laboratory, Department of Medicine, Brigham and Women's Hospital,1 and Department of Microbiology and Molecular Genetics,2 Harvard Medical School, Boston, Massachusetts 02115
Received 5 May 2000/Returned for modification 21 July 2000/Accepted 2 August 2000
| |
ABSTRACT |
|---|
|
|
|---|
Bacteroides fragilis produces a capsular polysaccharide complex (CPC) that is directly involved in its ability to induce abscesses. Two distinct capsular polysaccharides, polysaccharide A (PS A) and PS B, have been shown to be synthesized by the prototype strain for the study of abscesses, NCTC9343. Both of these polysaccharides in purified form induce abscesses in animal models. In this study, we demonstrate that the CPC of NCTC9343 is composed of at least three distinct capsular polysaccharides: PS A, PS B, and PS C. A previously described locus contains genes whose products are involved in the biosynthesis of PS C rather than PS B as was originally suggested. The actual PS B biosynthesis locus was cloned, sequenced, and found to contain 22 genes in an operon-type structure. A mutant with a large chromosomal deletion of the PS B biosynthesis locus was created so that the contribution of PS B to the formation of abscesses could be assessed in a rodent model. Although purified PS B can induce abscesses, removal of this polysaccharide does not attenuate the organism's ability to induce abscesses.
| |
INTRODUCTION |
|---|
|
|
|---|
Bacteroides fragilis is the anaerobic species most frequently isolated from intra-abdominal abscesses. The capsular polysaccharide complex (CPC) of the prototype strain 9343 is the major virulence factor for abscess formation, and purified CPC stimulates the formation of abscesses in animal models (10). Two distinct capsular polysaccharides have been identified from strain NCTC9343: polysaccharide A (PS A) and PS B (12). The repeating units of PS A and PS B contain both positively and negatively charged groups (19). The presence of both types of charged groups is required for the induction of abscesses (18).
We characterized a locus of B. fragilis NCTC9343 that is
involved in the synthesis of a high-molecular-weight capsular
polysaccharide (4). This locus contains 16 genes, all
tightly clustered and transcribed from the same DNA strand, whose
products are similar to other products involved in polysaccharide
biosynthesis. No PS B was recovered from a mutant,
9343
wcfD-L, in which 10 genes of this locus were removed
(4). This finding, coupled with the putative functions of
the gene products encoded by the region and the belief that B. fragilis NCTC9343 produced only two capsular polysaccharides, led
us to conclude that this locus was involved in the synthesis of PS B. A
second mutant was created, 9343
wcfF, in which only a
single gene of the region was mutated. Using whole-organism antiserum
adsorbed with the 9343
wcfD-L mutant, we demonstrated that
the single-gene mutant was also unable to synthesize the high-molecular-weight polysaccharide encoded by this locus.
A second locus of strain NCTC9343, shown to be the biosynthesis locus of PS A, has been cloned and sequenced (unpublished data). In this report, we describe the characterization of a third capsular polysaccharide biosynthesis locus of NCTC9343. Current data demonstrate that this locus, rather than the previously characterized region (4), is the actual PS B biosynthesis locus. We demonstrate that the previously described region encodes gene products involved in the synthesis of a third, previously uncharacterized capsular polysaccharide, referred to here as PS C.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Bacteria, plasmids, and media.
The bacterial strains and
plasmids used in this study are described in Table
1. Escherichia coli strains
were grown in Luria (L) broth or on L agar plates. B. fragilis strains were grown anaerobically in basal medium
(12) or on brain heart infusion (BHI) agar plates
supplemented with 50 µg of hemin and 0.5 µg of menadione (BHIS) per
ml. The following concentrations of antibiotic supplements were added
when appropriate: ampicillin, 100 µg/ml; kanamycin, 20 µg/ml;
erythromycin, 5 µg/ml; trimethoprim, 100 µg/ml; and gentamicin, 200 µg/ml.
|
Transposon mutagenesis.
Transposon mutagenesis was performed
as previously described (4). E. coli DH5
containing pNJR6
4 and the conjugal helper plasmid R751 was mated
with B. fragilis US52540 overnight aerobically on BHIS
plates, plated onto BHIS containing erythromycin and gentamicin, and
incubated anaerobically. The resulting colonies were screened by colony
immunoblot with MAb G9 (11).
Cloning of DNA at the transposon junction of mutant 1-45.
The chromosome of mutant 1-45 (MAb G9-negative) yielded an
SstI fragment containing the origin of replication and the
Kmr gene of pNJR6, as well as ~8 kb of B. fragilis US52540 DNA. This fragment was cloned by ligation of
SstI-digested 1-45 chromosomal DNA (favoring intramolecular
ligations), transformation of E. coli DH5
, and selection
with kanamycin. EcoRI fragments of the resulting plasmid
(pLEC29) were subcloned into pBluescript II SK. Subclone pLEC29.4
contains a portion of the transposon and ~2 kb of US52540 DNA
immediately flanking the transposon. Plasmid pLEC29.2 contains a 3.7-kb
EcoRI insert that represents the US52540 DNA adjacent to
pLEC29.4. The 3.7-kb insert of pLEC29.2 was used as a probe to select
cosmid clones from a B. fragilis NCTC9343 cosmid genebank
constructed as previously described (4). Two cosmid clones
were selected: pLEC32 and pLEC33.
Construction of pLEC32 and pLEC33 subclones. EcoRI fragments of pLEC32 and pLEC33 were subcloned into pBluescript II SK. The plasmids used for sequencing template and their locations are diagrammed in Fig. 2 and described in Table 1.
Creation of deletion mutant 9343
PS B.
Mutant 9343
PS B
is devoid of six genes of the PS B locus beginning with wcfV
and continuing into wcgQ (see Fig. 2). To create this
mutant, a primer internal to and oriented upstream of wcfV (primer 2; XhoI,
5'-GGGACTCGAGGACACGACTATCGCAGCCATTCAAATAGGG) was
used in a PCR with primer 1 (BamHI,
5'-GCATGGATCCATACCACGCACCATGAAACGGGTACG) located
approximately 2.4 kb upstream of primer 2 (restriction sites are
underlined). A second PCR used a primer within wcgQ oriented
downstream (primer 3; XhoI,
5'-GAGACTCGAGAAGATAATCGGGGGGTGTCAATAGCCAGAG) with a primer located approximately 2.4 kb downstream of primer 3 (primer 4; BamHI,
5'-CAGAGGATCCGCTTTCGCCTCAACACCATTAGGTACAGAC) (restriction sites are underlined). PCRs with primers 1 and 2 and
primers 3 and 4 were performed with high-fidelity DNA polymerase (Life
Technologies, Gaithersburg, Md.). The PCR products were digested with
BamHI and XhoI and were gel purified. The
products were cloned by three-way ligation into the
Bacteroides suicide vector pJST55 (17) at the
BglII site. A plasmid containing the correct orientation of
the PCR products was selected by PCR and designated pLEC35. Plasmid
pLEC35 was introduced into NCTC9343 by mobilization from E. coli using the conjugal helper plasmid RK231. Cointegrates that
were formed by integration of the suicide plasmid into the chromosome
of NCTC9343 were detected by selection for stable Emr
colonies. The cointegrate was passaged three times in basal medium to
allow for resolution of the cointegrate and plated onto BHIS. The
resulting colonies were replica plated onto BHIS containing erythromycin, and the Ems colonies were tested for the
mutant genotype by PCR. The mutant with the wcfV-wcgQ region
deletion was designated 9343
PS B.
DNA sequencing and analyses. DNA sequencing and analyses were performed as described elsewhere (4).
SDS-PAGE and Western blotting (immunoblotting). Bacterial cell lysates were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on discontinuous SDS-polyacrylamide gels (4 to 20% gradient; ESA, Inc., Chelmsford, Mass.), and transferred to polyvinylidene difluoride (Immobilon) by standard techniques. Blots were blocked in Tris-buffered saline (TBS) containing 5% nonfat dry milk (TBS-milk) and then incubated for 1 h in TBS-milk containing primary antibody. The blots were washed with TBS and incubated with alkaline phosphatase-conjugated goat anti-mouse immunoglobulin G (Sigma Chemical Co.) at 1:1,000 in TBS for 1 h. After being washed again with TBS, the blots were developed with a colorimetric detection solution. Culture supernatants of monoclonal antibody (MAb) G9 (B. fragilis NCTC9343 PS B specific) and QUBF7 (B. fragilis NCTC9343 PS C specific [9]) were used at 1:50.
Mouse model of intra-abdominal abscess formation.
A
previously described animal model of intra-abdominal infection
(15) was modified for these studies. Briefly, male C57BL/6 mice (4 to 6 weeks old; Charles River Laboratories, Wilmington, Mass.)
were challenged via the intraperitoneal route with 0.1 ml of inoculum
containing 10-fold dilutions of NCTC9343 or 9343
PS B organisms mixed
1:1 (vol/vol) with sterilized rat fecal solution (SFC). SFC is used as
an adjuvant for abscess formation and does not induce abscesses when
implanted alone into the peritonea of mice. Six days after challenge,
the animals were necropsied and examined for intraabdominal abscesses.
The presence of one or more abscesses in an animal was scored as a
positive result. To compare the abscess-inducing potential of these
strains, a previously described mathematical model was used to
calculate the dose of bacteria required to induce abscesses in 50% of
animals (termed the AD50) (18).
| |
RESULTS |
|---|
|
|
|---|
The 9343
wcfF mutant strain, previously demonstrated
by Western blot to be devoid of a high-molecular-weight polysaccharide believed at the time to be PS B, was used in a large-scale fermentation for the isolation of PS A. Nuclear magnetic resonance analysis of the
capsular polysaccharides isolated from this strain clearly demonstrated
that PS B, in addition to PS A, was synthesized by 9343
wcfF. This unexpected finding led to a reevaluation
of the designation of the PS B locus and a search for the actual locus involved in the synthesis of PS B.
Cloning of the PS B biosynthesis locus of NCTC9343.
Pantosti
et al. described an MAb, G9, that reacted with the PS B of B. fragilis NCTC9343 (11). We previously demonstrated that
the 9343
wcfD-L and 9343
wcfF mutants also
reacted with MAb G9; however, we attributed this to cross-reactivity
with PS A, which we had previously demonstrated using purified
polysaccharide in Western blots (4). Recent data suggest
that the reactivity of MAb G9 with purified PS A by Western blot is an
artifact. We have determined that MAb G9 does not react with purified
PS A by enzyme-linked immunosorbent assay or on the surface of the bacteria (data not shown). These data demonstrate that MAb G9 is PS B
specific, as originally described. Therefore, it became clear that the
previously cloned region, a mutant of which retains MAb G9 reactivity,
is not the biosynthesis locus of PS B. In order to clone the PS B
biosynthesis locus of NCTC9343, we selected transposon mutants that no
longer reacted with MAb G9. Since NCTC9343 is somewhat resistant to the
introduction of foreign DNA, transposon mutagenesis of this strain is
difficult. B. fragilis US52540, which also produces a
high-molecular-weight capsular polysaccharide that reacts specifically
with MAb G9, was used for transposon mutagenesis.
1,2-fucosyltransferases. Since the
repeating unit of PS B contains a terminal fucose with an
1-2
linkage to galacturonic acid, this finding provided evidence that
this transposon had inserted into the PS B biosynthesis locus. An
EcoRI subclone of pLEC29 (pLEC29.4) was used as a
probe to select NCTC9343 gene bank clones pLEC32 and pLEC33. All
subsequent analyses and DNA sequences were performed only with DNA from
strain NCTC9343. The cosmid clones were subcloned as indicated in Fig.
2 and used as sequencing template. In
total, 26,041 bp were sequenced. Analysis of this sequence revealed 22 ORFs, most of which encode putative products with various degrees
of similarity to proteins implicated in polysaccharide biosynthesis
in other organisms (Table 2). These
22 ORFs are all oriented in the same direction and are tightly clustered. These genetic characteristics are similar to those of the
other capsular polysaccharide biosynthesis locus sequenced from
NCTC9343 and suggest that this region is an operon. The genes were
named in accordance with the nomenclature of polysaccharide biosynthesis genes (13).
|
|
|
NCTC9343 PS B mutant and analysis of phenotype.
Mutant 1-45 (MAb G9 negative) was created using strain US52540. To determine
whether a mutation in the homologous region of the NCTC9343 chromosome
would yield a similar phenotype, a deletion mutant was created in which
six genes (wcfV to wcgQ) of the NCTC9343 chromosome were removed (Fig. 2). This mutant was demonstrated by
Western blot to be MAb G9 negative (Fig. 1A) and was therefore designated 9343
PS B. We have determined that a previously
described MAb, designated QUBF7 (9), does not react with the
9343
wcfF or 9343
wcfD-L mutants (Fig.
1B). Therefore, this MAb is specific for the polysaccharide encoded by
the polysaccharide biosynthesis locus originally believed to be PS B. MAb QUBF7 reacts with 9343
PS B; this reaction demonstrates that the
previously identified genetic region and the PS B locus encode separate
polysaccharides identifiable with distinct MAbs. Several previous
findings indicate that the QUBF7-reactive polysaccharide encoded by the
previously described genetic locus is also a capsular polysaccharide.
Lutton et al. showed by electron microscopic analysis of colloidal
gold-labeled bacteria that MAb QUBF7 reacts with the bacterial cell
surface. Additionally, these authors demonstrated that MAb QUBF7 reacts with a high-molecular-weight polysaccharide. We have also shown by
immunoadsorption that the previously cloned locus encodes a high-molecular-weight surface polysaccharide (4). On the
basis of these data, the polysaccharide encoded by the previously
described locus, which is MAb QUBF7 reactive, is designated PS C.
Abscess induction by 9343
PS B.
We showed that a PS C mutant
(9343
wcfF) was still fully virulent in an animal model of
abscess formation compared with wild-type NCTC9343 (4).
Since the structure of PS C has still not been determined, it is
possible that this polysaccharide does not contain the necessary charge
motif for abscess induction. If so, its removal would not be expected
to diminish abscess formation. PS B, however, does contain the
necessary charge motif for the induction of abscesses, and purified PS
B elicits abscesses in rodent models (18). To assess the
contribution of PS B to abscess formation in the context of intact
bacteria, where other capsular polysaccharides are expressed, both
NCTC9343 and 9343
PS B were tested in the rodent model. The results
showed that the PS B mutant strain retains the full virulence of the
wild-type, yielding AD50s of 105.1 and
105.2, respectively (Table 2).
| |
DISCUSSION |
|---|
|
|
|---|
The CPC of B. fragilis has been demonstrated to be composed of two capsular polysaccharides: PS A and PS B. We provide data demonstrating that the prototype organism for the study of abscess formation, B. fragilis NCTC9343, synthesizes at least three capsular polysaccharides: the previously described PS A and PS B, as well as the newly recognized PS C. Genetic and MAb analyses have revealed that a previously described capsular polysaccharide biosynthesis locus sequenced from B. fragilis NCTC9343 is involved in the synthesis of PS C and not PS B. The data clearly demonstrate that the locus described herein is the actual PS B locus. In addition to the nonreactivity of a deletion mutant lacking this region with the PS B-specific MAb G9, the presence of genes whose putative products are similar to those necessary for the synthesis of PS B constitutes further evidence that this region is the PS B biosynthesis locus. In light of these data, the previously described PS B2 region of B. fragilis 638R (3) will similarly be renamed the PS C2 biosynthesis locus.
The PS B of NCTC9343 is composed of the repeating unit
[
4)
-L-QuipNAc(1
3)
-D-QuipNAc(1
4)[
-L-Fucp(1
2)
-D-GalpA(1
3)
-D-GlcpNAc(1
3)]
-D-Galp(1
], with a 2-aminoethylphosphonate
(AEP) substituent on O-4 of the
N-acetyl-
-D-glucopyranosyl residue
(19). The PS B locus contains three genes, designated aepX, aepY, and aepZ, that encode
putative products highly similar to three products involved in the
formation of AEP (Table 2). The presence of these genes in this locus
was not anticipated since they had not previously been found within a
bacterial polysaccharide biosynthesis locus; however, their presence
further identifies this region as the PS B locus.
This locus also contains other genes whose presence was anticipated given the structure of PS B; wcfX and wcfY are adjacent genes with nearly identical G+C contents which significantly differ from that of the surrounding genes (Fig. 1), suggesting that products of these genes may function in a common pathway. On the basis of the PS B structure and the proposed functions of the homologs of these gene products, we propose that WcfY is a UDP-glucose dehydrogenase that converts UDP-glucose to UDP-glucuronic acid, which is then epimerized by WcfX to UDP-galacturonic acid, one of the nucleotide sugar precursors of PS B.
The product of wcfW is similar to a family of
1,2-fucosyltransferases. The presence of this gene in the PS B locus
was expected since its product is necessary for formation of the
1,2
linkage of the terminal L-fucose to
D-galacturonic acid. Genes that encode products with
putative functions similar to those of WcfY and WcfW are also found in
the PS C biosynthesis locus and contributed to the misidentification of
the region.
In addition to WcfY, the putative
1,2-fucosyltransferase, five other
genes (wcfZ, wcgQ, wcgR,
wcgV, and wcgX) encode products with similarity
to glycosyltransferases. Unlike the PS C region, which contains seven
genes whose products are similar to glycosyltransferases, the PS B
region contains the expected number of glycosyltransferases for the
transfer of the six residues in the assembly of the repeating unit of
PS B.
Three genes of the PS B locus encode products with nine or more predicted membrane-spanning domains: wzy, wzx, and wcfT. Wzy and Wzx were assigned as the putative polymerase and flippase, respectively, based on their size, low G+C content, and similarity to other products assigned to these functions (Table 2). The third highly hydrophobic protein encoded within this region, WcfT, has 12 potential membrane-spanning domains. Homologs of this protein have not been described in other bacterial polysaccharide biosynthesis loci. However, in our description of the PS C biosynthesis locus of NCTC9343 (4), we reported the sequence of a partial gene, designated orf1, that is approximately 1.8 kb upstream of the PS C biosynthesis region and is transcribed in the opposite direction from the PS C biosynthesis genes. The product of orf1 is also predicted to span the membrane multiple times and is 62% similar to WcfT.
The repeating unit of PS B contains both L-N-acetylquinovosamine (L-QuipNAc) and D-N-acetylquinovosamine (D-QuipNAc). The biosynthesis pathways for the nucleotide precursors of these two residues have not been reported. Given the structures of the polysaccharides whose loci contain homologs of these genes, it is likely that wcgW encodes a 6-dehydratase involved in the direct conversion of UDP-D-N-acetylglucosamine to UDP-D-QuiNAc. Similarly, we predict that the products of three clustered genes, wcgS, wcgT, and wcgU, which are similar to a 4,6-dehydratase, a 3,5-epimerase, and a 4-reductase, respectively, are involved in the formation of UDP-L-QuiNAc from UDP-D-N-acetylmannosamine.
The only sugar residue of the PS B repeating unit whose nucleotide
sugar precursor would not be synthesized by products encoded by the PS
B locus is L-fucose. In the synthesis of colanic acid of
E. coli, the products of two genes, gmd and
fcl, have been shown to convert GDP-D-mannose
to GDP-L-fucose in a three-step reaction (1).
No homologs of gmd or fcl were found in the PS B
biosynthesis locus and are likely present elsewhere on the chromosome. The PS C locus, which also contains a gene whose product is similar to
1,2 fucosyltransferases, likewise does not contain gmd or fcl homologs.
Comparison of the PS B locus to the PS C locus of strain NCTC9343 has
revealed that not only are the terminal two genes of each locus highly
similar at the protein level (Table 3),
but also that the DNA regions comprising these genes are 76.1%
identical between loci. We predict that the products of wcgW
and wcgX of the PS B locus are involved in the synthesis and
transfer of UDP-D-QuiNAc to undecaprenylphosphate as the
first step in the synthesis of the PS B repeating unit. Based on the
similarity of these gene products, we predict that the PS C of NCTC9343
will also contain D-QuiNAc.
|
The overall genetic composition of the PS B biosynthesis locus has similarities to the biosynthesis loci of other bacteria. The exceptions are the aminoethylphosphonate biosynthesis genes (aepX, aepY, and aepZ), wcfT (predicted to encode a transmembrane product), and wcfV, for which no homologs are present in the database. Comparison of the NCTC9343 PS B locus with the only other reported polysaccharide biosynthesis loci of B. fragilis, PS C1 of NCTC9343 and PS C2 of strain 638R, reveals that the genes of all three loci are organized in an operon type structure in that all genes are oriented in the same direction and tightly clustered. The genetic complement of these three loci, however, differ as the repeating units of each of these capsular polysaccharides are structurally and serologically distinct. Products similar to sugar dehydrogenases are encoded by all three loci. These products likely confer a negative charge to the repeating unit of each of the respective polysaccharides. This negative charge is part of the motif necessary for abscess induction.
The genetic arrangement of the PS C biosynthesis locus has been analyzed for 50 B. fragilis strains. Two small genes, previously designated orf3 and orf4, were found just upstream of the PS C biosynthesis genes in all 50 strains analyzed, regardless of the variability of the downstream PS C biosynthesis genes (5). We have redesignated orf3 and orf4 as upcY and upcZ (designation derived from upstream PS C), respectively. The PS B biosynthesis locus similarly contains homologs of these two genes just upstream of the PS B biosynthesis genes. These genes have therefore been designated upbY and upbZ (designation derived from upstream PS B). Future studies will examine the prevalence of upbY and upbZ to determine whether these genes are upstream of the PS B biosynthesis genes in all B. fragilis strains.
Purified PS A and PS B have each been shown to be potent
abscess-inducing polysaccharides. In the rat intra-abdominal abscess model, the AD50 of purified PS A is 0.67 µg, whereas the
AD50 of PS B is 25 µg (18). We found the PS C
mutant (9343
wcfF) to be fully virulent in the rodent
abscess model. Since the structure of the PS C of NCTC9343 has not
been determined, it is possible that it does not have the
necessary charge motif for the induction of abscesses. Moreover, as PS
A and PS B continue to be expressed by this mutant, it would be
expected to retain some abscess-inducing ability. The present study
indicates that the PS B mutant is fully virulent in the rodent abscess
model. Although purified PS B does induce abscesses, the more potent PS
A is probably responsible for the abscess-inducing ability of the PS B
mutant. Mutants deficient in the synthesis of two or more of these
capsular polysaccharides may be necessary for the production of an
attenuated strain.
| |
ACKNOWLEDGMENTS |
|---|
We are grateful to Vincent Carey for aid in statistical analysis of animal data, to Sheila Patrick for supplying MAb QUBF7, and to Michael Malamy for plasmid pJST55.
This work was supported by the Edward and Amalie Kass Fellowship and by Public Health Service grants AI44193 and AI39576 from the National Institute of Allergy and Infectious Diseases.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Channing Laboratory, 181 Longwood Ave., Boston, MA 02115. Phone: (617) 525-2679. Fax: (617) 731-1541. E-mail: lcomstock{at}channing.harvard.edu.
Editor: R. N. Moore
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Andrianipoulos, K.,
L. Wang, and P. R. Reeves.
1998.
Identification of the fucose synthetase gene in the colanic acid gene cluster of Escherichia coli K-12.
J. Bacteriol.
180:998-1001 |
| 2. |
Bethesda Research Laboratories.
1986.
BRL pUC host: E. coli DH5 competent cells.
Focus
8:9.
|
| 3. |
Comstock, L. E.,
M. J. Coyne,
A. O. Tzianabos, and D. L. Kasper.
1999.
Interstrain variation of the polysaccharide B biosynthesis locus of Bacteroides fragilis: characterization of the region from strain 638R.
J. Bacteriol.
181:6192-6196 |
| 4. |
Comstock, L. E.,
M. J. Coyne,
A. O. Tzianabos,
A. Pantosti,
A. B. Onderdonk, and D. L. Kasper.
1999.
Analysis of a capsular polysaccharide biosynthesis locus of Bacteroides fragilis.
Infect. Immun.
67:3525-3532 |
| 5. |
Comstock, L. E.,
A. Pantosti, and D. L. Kasper.
2000.
Genetic diversity of the capsular polysaccharide C biosynthesis region of Bacteroides fragilis.
Infect. Immun.
68:6182-6188 |
| 6. | Guiney, D., P. Hasegawa, and C. Davis. 1984. Plasmid transfer from Escherichia coli to Bacteroides fragilis: differential expression of antibiotic resistance phenotypes. Proc. Natl. Acad. Sci. USA 83:7203-7206. |
| 7. | Hohn, B., and J. Collins. 1980. A small cosmid for efficient cloning of large DNA fragments. Gene 11:291-298[CrossRef][Medline]. |
| 8. | Johnson, J. L. 1978. Taxonomy of the Bacteroides. I. Deoxyribonucleic acid homologies among Bacteroides fragilis and other saccharolytic Bacteroides species. Int. J. Syst. Bacteriol. 28:245-268[CrossRef]. |
| 9. | Lutton, D., S. Patrick, A. Crockard, L. Stewart, M. Larkin, E. Dermott, and T. McNeill. 1991. Flow cytometric analysis of within-strain variation in polysaccharide expresion by Bacteroides fragilis by use of murine monoclonal antibodies. J. Med. Microbiol. 35:229-237[Abstract]. |
| 10. | Onderdonk, A. B., D. L. Kasper, R. L. Cisneros, and J. G. Bartlett. 1977. The capsular polysaccharide of Bacteroides fragilis as a virulence factor: comparison of the pathogenic potential of encapsulated and unencapsulated strains. J. Infect. Dis. 136:82-89[Medline]. |
| 11. | Pantosti, A., R. Colangeli, A. O. Tzianabos, and D. L. Kasper. 1995. Monoclonal antibodies to detect capsular diversity among Bacteroides fragilis isolates. J. Clin. Microbiol. 33:2647-2652[Abstract]. |
| 12. |
Pantosti, A.,
A. O. Tzianabos,
A. B. Onderdonk, and D. L. Kasper.
1991.
Immunochemical characterization of two surface polysaccharides of Bacteroides fragilis.
Infect. Immun.
59:2075-2082 |
| 13. | Reeves, P. R., M. Hobbs, M. A. Valvano, M. Skurnik, C. Whitfield, D. Coplin, N. Kido, J. Klena, D. Maskell, C. R. H. Raetz, and P. D. Rick. 1996. Bacterial polysaccharide synthesis and gene nomenclature. Trends Microbiol. 4:495-503[CrossRef][Medline]. |
| 14. | Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Press, Cold Spring Harbor, N.Y. |
| 15. | Shapiro, M. E., D. L. Kasper, D. F. Zaleznik, S. Spriggs, A. B. Onderdonk, and R. W. Finberg. 1986. Cellular control of abscess formation: role of T cells in the regulation of abscesses formed in response to Bacteroides fragilis. J. Immunol. 137:341-346[Abstract]. |
| 16. |
Shoemaker, N. B.,
C. E. Getty,
A. A. Salyers, and J. F. Gardner.
1985.
Evidence that the clindamycin-erythromycin resistance gene of Bacteroides plasmid pBF4 is on a transposable element.
J. Bacteriol.
162:626-632 |
| 17. |
Thompson, J. S., and M. H. Malamy.
1990.
Sequencing the gene for an imipenem-cefoxitin-hydrolyzing enzyme (CfiA) from Bacteroides fragilis.
J. Bacteriol.
172:2584-2593 |
| 18. |
Tzianabos, A. O.,
A. B. Onderdonk,
B. Rosner,
R. L. Cisneros, and D. L. Kasper.
1993.
Structural features of polysaccharides that induce intra-abdominal abscesses.
Science
262:416-419 |
| 19. |
Tzianabos, A. O.,
A. Pantosti,
H. Baumann,
J. R. Brisson,
H. J. Jennings, and D. L. Kasper.
1992.
The capsular polysaccharide of Bacteroides fragilis comprises two ionically linked polysaccharides.
J. Biol. Chem.
267:18230-18235 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|